Organization
Chris O'Brien Lifehouse
23 abstracts
Abstract
A randomised, controlled, multicentre trial of imiquimod versus radiotherapy for lentigo maligna.Org: Melanoma Institute Australia, The University of Sydney, Chris O'Brien Lifehouse, Icon Cancer Centre, Faculty of Medicine and Health, The University of Sydney,
Abstract
Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial.Org: Memorial Sloan Kettering Cancer Center, Chris O'Brien Lifehouse, Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Medical Oncology and Sarcoma Center, Dana-Farber Cancer Institute,
Abstract
SU2C-SARC032: A randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma.Org: UPMC Hillman Cancer Center, Mayo Clinic Rochester, Melanoma Institute Australia, University of Sydney and Sydney Cancer Centre, Chris O'Brien Lifehouse,
Abstract
Cost-effectiveness of an oral THC: CBD cannabis extract for secondary prevention of refractory, chemotherapy-induced nausea and vomiting.Org: The University of Sydney, Chris O'Brien Lifehouse, NHMRC Clinical Trials Centre,
Abstract
Biomarker assessment and pharmacology of HP518, an AR PROTAC degrader from the phase 1 dose-escalation study in patients with metastatic castration-resistant prostate cancer (mCRPC).Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Border Medical Oncology Research Unit, Albury Wodonga Regional Cancer Centre & Rural Medical School, Albury Campus, University of New South Wales, Albury-Wodonga, NSW, Australia, Department of Clinical Medicine and Surgery, Università Federico II, Napoli, Italy, Chris O'Brien Lifehouse, The Alfred Hospital,
Abstract
Use of early circulating tumour DNA dynamics in patients with stage III melanoma receiving neoadjuvant combination immunotherapy.Org: Macquarie University, Chris O'Brien Lifehouse, Melanoma Institute Australia, Netherlands Cancer Institute (NKI-AVL),
Abstract
Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program.Org: Garvan Institute of Medical Research, The Kinghorn Cancer Centre, Chris O'Brien Lifehouse, Royal North Shore Hospital, Sydney, Australia, Westmead Cancer Care Centre,
Abstract
Intracranial and systemic efficacy of repotrectinib in advanced ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Memorial Sloan Kettering Cancer Center, Vall d’Hebron University Hospital/VHIO, Netherlands Cancer Institute, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China,
Abstract
Tarlatamab in small cell lung cancer (SCLC): Safety and efficacy analyzed by baseline brain metastasis.Org: Gustave Roussy Département d'Organisation du Parcours Patient, Chris O'Brien Lifehouse, Washington University Medical School, Hospital Universitario 12 de Octubre, University of Pittsburgh School of Medicine,
Abstract
Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy.Org: Garvan Institute of Medical Research, Brain and Mind Centre, The University of Sydney, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Prince of Wales Hospital,
Abstract
CLIMATE: Assessing the clinical utility of miR-371a-3p as a marker of residual disease in stage 1 testicular germ cell tumour (TGCT) following orchiectomy: ANZUP 1906.Org: Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Chris O'Brien Lifehouse, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, Princess Alexandra Hospital & University of Queensland,
Abstract
Cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: Results of a phase II/III, placebo-controlled, randomised trial.Org: NHMRC Clinical Trials Centre, The University of Sydney, Northern Beaches Hospital, University of Adelaide, Campbelltown Hospital,
Abstract
Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program.Org: NHMRC Clinical Trials Centre, The University of Sydney, Garvan Institute of Medical Research, The NHMRC Clinical Trials Centre, Rare Cancer Laboratory,
Abstract
Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program.Org: Austin Health and Peter MacCallum Cancer Centre, Melbourne, Australia, Garvan Institute of Medical Research, Sydney, Australia, The Kinghorn Cancer Centre,
Abstract
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs).Org: NHMRC Clinical Trials Centre, The University of Sydney, Peter MacCallum Cancer Centre, Melbourne, Australia, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Yale School of Medicine,
Abstract
Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.Org: NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia, Sydney, Australia, Garvan Institute of Medical Research,
Abstract
A phase Ib/II study of GFH018 in combination with toripalimab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).Org: Sun Yat-sen University Cancer Center (China), Guangzhou, No, China National Biotec Group, Shanghai East Hospital, Tongji University, Shanghai, China, Tongji University School of Medicine,
Abstract
A phase 2, open-label, adaptive, dose-ranging study with long-term extension to evaluate the safety, tolerability, efficacy, and pharmacokinetics of intra-articular AMB-05X injections in patients with tenosynovial giant cell tumor.Org: LUMC Leids Universitair Medisch Centrum, Chris O'Brien Lifehouse, University of California, Davis, Ohio State University Comprehensive Canvcer Hospital, Sarcoma Medical Oncology Service,
Abstract
GUIDE: A randomized non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (ANZUP 1903).Org: Australian & New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Chris O'Brien Lifehouse, Garvan Institute of Medical Research, Centre for Biostatistics and Clinical Trials, Peter Maccallum Cancer Centre, Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Center,
Abstract
A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in high-risk stage II cutaneous melanoma: NeoReNi II.Org: Melanoma Institute Australia, Royal Prince Alfred Hospital, Camperdown, NSW, Australia, Chris O'Brien Lifehouse, The University of Sydney, The Mater Hospital Sydney,
Abstract
Implementation study of a novel brief clinician intervention to reduce fear of recurrence in cancer survivors (CIFeR_2 Implementation Study).Org: The Kinghorn Cancer Centre, St Vincent's Hospital, Darlinghurst, NSW, Australia, Chris O'Brien Lifehouse, Camperdown, NSW, Australia,
Abstract
Association of common inherited NOD2 mutations with exceptional response to immune checkpoint inhibitors.Org: Garvan Institute of Medical Research, Darlinghurst, NSW, Australia, NHMRC Clinical Trials Centre, The University of Sydney, Princess Margaret Cancer Centre,
Abstract
Circulating ether lipids in prostate cancer.Org: Chris O'Brien Lifehouse, Garvan Institute of Medical Research, Baker Institute, Baker Heart and Diabetes Institute, St Vincent's Hospital,